Keytruda (pembrolizumab)
pCPA File Number:
22099
Negotiation Status:
Concluded with an LOI
Indication(s):
Persistent, recurrent, or metastatic cervical cancer whose tumours express PD‐L1 (CPS ≥ 1) as determined by a validated test, in combination with chemotherapy with or without bevacizumab, in adult patients
Sponsor/Manufacturer:
Merck Canada Inc.
CDA-AMC Project Number:
PC0292-000
pCPA Engagement Letter Issued:
Negotiation Process Concluded: